NASDAQ:CMPS Compass Pathways (CMPS) Stock Price, News & Analysis $9.01 -0.11 (-1.21%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$8.93 -0.08 (-0.93%) As of 11/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Compass Pathways Stock (NASDAQ:CMPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Compass Pathways alerts:Sign Up Key Stats Today's Range$8.53▼$9.1650-Day Range$7.81▼$15.1952-Week Range$4.88▼$15.87Volume2.62 million shsAverage Volume3.80 million shsMarket Capitalization$1.28 billionP/E RatioN/ADividend YieldN/APrice Target$23.14Consensus RatingModerate Buy Company Overview Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder. Compass Pathways is headquartered in the United Kingdom and conducts clinical development internationally, including in the United States and Europe. Kabir Nath became the company’s chief executive officer in 2023. COMP360 is investigational and has not been approved for commercial use.AI Generated. May Contain Errors. Read More Compass Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreCMPS MarketRank™: 2.817955112215 of 5 starsCompass Pathways scored higher than 56% of companies evaluated by MarketBeat, and ranked 441st out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCompass Pathways has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCompass Pathways has a consensus price target of $23.14, representing about 156.9% upside from its current price of $9.01.Amount of Analyst CoverageCompass Pathways has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Pathways' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Pathways are expected to decrease in the coming year, from ($0.78) to ($1.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Pathways is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Pathways is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Pathways has a P/B Ratio of 9.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.49% of the float of Compass Pathways has been sold short.Short Interest Ratio / Days to CoverCompass Pathways has a short interest ratio ("days to cover") of 7.73.Change versus previous monthShort interest in Compass Pathways has recently decreased by 2.65%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Pathways does not currently pay a dividend.Dividend GrowthCompass Pathways does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentCompass Pathways has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Compass Pathways this week, compared to 5 articles on an average week.Search InterestOnly 17 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat Follows7 people have added Compass Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compass Pathways insiders have not sold or bought any company stock.Percentage Held by Insiders2.82% of the stock of Compass Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of Compass Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Pathways and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPS Stock News HeadlinesEquities Analysts Offer Predictions for CMPS FY2026 EarningsNovember 13 at 1:43 AM | americanbankingnews.comCOMPASS Pathways (CMPS) Could Be 62% Undervalued As FDA Filing Sharpens The CaseNovember 12 at 6:42 PM | finance.yahoo.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 15 at 1:00 AM | Base Camp Trading (Ad)Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19thNovember 11, 2026 | businesswire.comHC Wainwright Reaffirms Buy Rating for Compass Pathways (NASDAQ:CMPS)November 11, 2026 | americanbankingnews.comCompass Pathways stock gains on FDA filing for depression drugNovember 9, 2026 | finance.yahoo.comCompass Pathways Submits NDA for COMP360 Psilocybin to FDA for Treatment-Resistant DepressionNovember 9, 2026 | marketscreener.comMCompass Pathways could secure US approval for depression drug by early 2027, Jefferies saysNovember 9, 2026 | finance.yahoo.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? Compass Pathways' stock was trading at $6.90 at the beginning of the year. Since then, CMPS shares have increased by 30.6% and is now trading at $9.01. How were Compass Pathways' earnings last quarter? Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) posted its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. Read the conference call transcript. When did Compass Pathways IPO? Compass Pathways (CMPS) raised $112 million in an IPO on Friday, September 18th 2020. The company issued 7,500,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Compass Pathways' major shareholders? Top institutional shareholders of Compass Pathways include Candriam S.C.A. (1.09%), Creek Drive Management Group LLC (0.94%), Marshall Wace LLP (0.90%) and Jefferies Financial Group Inc. (0.64%). Insiders that own company stock include Life Sciences NV Atai, Ekaterina Malievskaia and George Jay Goldsmith. View institutional ownership trends. How do I buy shares of Compass Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Pathways investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), CrowdStrike (CRWD) and Definium Therapeutics (DFTX). Company Calendar Last Earnings11/03/2026Today11/15/2026Jefferies Global Healthcare Conference11/18/202638th Annual Healthcare Conference12/01/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 13 days, CMPS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees156Year Founded2016Price Target and Rating Average Price Target for Compass Pathways$23.14 High Price Target$65.00 Low Price Target$10.00 Potential Upside/Downside+156.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($3.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-18.03% Return on Assets-5.11% Debt Debt-to-Equity Ratio0.35 Current Ratio1.50 Quick Ratio1.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book9.01Miscellaneous Outstanding Shares141,710,000Free Float137,714,000Market Cap$1.28 billion OptionableOptionable Beta2.43 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CMPS) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Pathways With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPS Stock Alerts